Form 4 for RMD ResMed|
Accepted 2023-11-20 00:00:00 ET · period of report 2023-11-16 · accession 0001127602-23-028004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-20 | 2023-11-20 | RMD | Farrell Michael J. | CEO | F - Tax | $148.94 | -2,353 | 438.6K | -0.5% | -$350.4K |
| D | 2023-11-20 | 2023-11-16 | RMD | Farrell Michael J. | CEO | A - Grant | $148.90 | +55.5K | 55.5K | New | +$8.26M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | ResMed Common Stock | 2023-11-20 | F | D | 2,352.93 | $148.94 | 438,633 | D | — | — | |
| 2 | Derivative | ResMed Common Stock Options | 2023-11-16 | A | A | 55,468 | $148.90 | 55,468 | D | $148.90 · 2024-11-11 to 2030-11-16 | 55,468 ResMed Common Stock | (F2) Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2024, 2025, and 2026. |